Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
European Journal of Dermatology : EJD|December 16, 2014
Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroidsFrançois Chasset, Cécile Pages, Lucie Biard, et al.
Melanoma Research|October 17, 2017
Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combinationJeremy Lupu, Cécile Pages, Pauline Laly, et al.
Experimental Dermatology|April 10, 2016
EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanomaAnne Caudron, Maxime Battistella, Jean-Paul Feugeas, et al.
International Immunopharmacology|October 12, 2016
Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapyJoana Felix, Bruno Cassinat, Raphael Porcher, et al.
Cancers|June 2, 2021
Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma ProtuberansJessica Beaziz, Maxime Battistella, Julie Delyon, et al.
Oncoimmunology|September 14, 2016
Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical responseJoana Felix, Jérome Lambert, Marie Roelens, et al.
Melanoma Research|July 11, 2017
Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanomaMarie-Léa Gauci, Pauline Laly, Sarah Leonard-Louis, et al.
Cancer Immunology, Immunotherapy : CII|June 22, 2017
Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature reviewMarie-Léa Gauci, Pauline Laly, Tiphaine Vidal-Trecan, et al.
Cancer Immunology, Immunotherapy : CII|May 30, 2018
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective studyMarie-Léa Gauci, Philippe Boudou, Barouyr Baroudjian, et al.
Pageof 2